Dyne therapeutics news
WebMar 2, 2024 · Fourth Quarter and Full Year 2024 Financial Results. Cash position: Cash, cash equivalents and marketable securities were $256.0 million as of December 31, 2024, which is anticipated to fund ... WebOct 31, 2024 · Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to …
Dyne therapeutics news
Did you know?
WebMar 23, 2024 · Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. ... ABC News' '20/20 ... WebDyne Therapeutics Inc Working Capital Per Revenue on the trailing twelve month basis from the forth quarter 2024 to forth quarter 2024, Trends and Ranking, Fundamental Ratios - CSIMarket
WebView the latest Dyne Therapeutics Inc. (DYN) stock price, news, historical charts, analyst ratings and financial information from WSJ. WebSep 13, 2024 · Summary. Dyne Therapeutics had filed proposed terms for a $175 million U.S. IPO. The firm is advancing treatments for various muscle diseases. DYN has yet to enter Phase 1 safety trials, so the ...
WebApr 11, 2024 · Let’s start up with the current stock price of Dyne Therapeutics Inc. (DYN), which is $8.82 to be very precise. The Stock rose vividly during the last session to $9.35 … WebApr 11, 2024 · A high-level overview of Dyne Therapeutics, Inc. (DYN) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and …
WebNov 3, 2024 · WALTHAM, Mass., Nov. 03, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today reported financial results for the third quarter of 2024 and business …
WebDyne Therapeutics Inc is a bio-technology company focused on providing therapeutics for patients with genetically driven diseases. The company is developing therapies for muscle disorders like ... how to say black coffee in spanishWebApr 13, 2024 · Dyne Therapeutics Inc (DYN) stock is trading at $8.97 as of 3:43 PM on Thursday, Apr 13, a gain of $0.44, or 5.19% from the previous closing price of $8.53. The … how to say black in arabicWebApr 13, 2024 · Quoin Pharmaceuticals presently has a consensus price target of $17.50, indicating a potential upside of 3,788.89%. Nyxoah has a consensus price target of … north fork li restaurantsWebApr 10, 2024 · 5 brokerages have issued twelve-month target prices for Dyne Therapeutics' shares. Their DYN share price forecasts range from $18.00 to $34.00. On average, they … how to say black eyes in spanishWebMar 23, 2024 · Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to … north fork lone pine creek trailWebMar 20, 2024 · Dyne links therapeutic payloads to its TfR1-binding fragment antibody (Fab) to develop targeted therapeutics for muscle diseases. About DYNE-101 and the ACHIEVE Trial. DYNE-101 is an investigational therapeutic being evaluated in the Phase 1/2 global ACHIEVE trial, for people living with myotonic dystrophy type 1 (DM1). north fork libraryWebApr 11, 2024 · On average, analysts predict that Dyne Therapeutics will post -3.23 EPS for the current year. Insider Activity at Dyne Therapeutics. In related news, insider Jonathan Mcneill sold 10,000 shares of the company's stock in a transaction dated Wednesday, January 18th. The shares were sold at an average price of $14.03, for a total value of … north fork local school district tax number